Which has preferable earnings and valuation, CMPS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is CMPS or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Belite Bio N/A -11.84% -11.62%

Does the media favor CMPS or BLTE?

In the previous week, Compass Pathways had 5 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Compass Pathways and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.77 beat Compass Pathways' score of 0.04 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LNTH or CMPS more profitable?

Lantheus has a net margin of 17.69% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Compass Pathways N/A -49.63% -13.08%

Does the media favor LNTH or CMPS?

In the previous week, Compass Pathways had 6 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Compass Pathways and 1 mentions for Lantheus. Lantheus' average media sentiment score of 0.84 beat Compass Pathways' score of 0.04 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CMPS or LQDA?

In the previous week, Liquidia had 4 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Liquidia and 7 mentions for Compass Pathways. Liquidia's average media sentiment score of 0.74 beat Compass Pathways' score of 0.04 indicating that Liquidia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CMPS or AMRX?

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 7 mentions for Compass Pathways. Amneal Pharmaceuticals' average media sentiment score of 0.49 beat Compass Pathways' score of 0.04 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, DFTX or CMPS?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is DFTX or CMPS more profitable?

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Compass Pathways N/A -49.63% -13.08%

Does the media prefer DFTX or CMPS?

In the previous week, Definium Therapeutics had 37 more articles in the media than Compass Pathways. MarketBeat recorded 44 mentions for Definium Therapeutics and 7 mentions for Compass Pathways. Definium Therapeutics' average media sentiment score of 0.34 beat Compass Pathways' score of 0.04 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 8 Very Positive mention(s) 11 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 5 Very Negative mention(s) Neutral Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compass Pathways (CMPS) Competitors

$15.19 +0.19 (+1.27%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$15.19 0.00 (-0.01%)

As of 09/18/2026 07:56 PM Eastern

Compare

CMPS vs. BLTE, LNTH, LQDA, AMRX, and DFTX

Should you buy Compass Pathways stock or one of its competitors? Compass Pathways's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Compass Pathways compare to Belite Bio?

Compass Pathways (NASDAQ:CMPS) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Compass Pathways has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

In the previous week, Compass Pathways had 5 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Compass Pathways and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.77 beat Compass Pathways' score of 0.04 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio's return on equity of -11.84% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Belite Bio	N/A	-11.84%	-11.62%

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Compass Pathways currently has a consensus price target of $23.36, indicating a potential upside of 53.77%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 27.94%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

Compass Pathways beats Belite Bio on 8 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Compass Pathways (NASDAQ:CMPS) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Compass Pathways had 6 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Compass Pathways and 1 mentions for Lantheus. Lantheus' average media sentiment score of 0.84 beat Compass Pathways' score of 0.04 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.26	$233.56M	$4.14	24.29
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.54, indicating that its stock price is 154% more volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Compass Pathways	N/A	-49.63%	-13.08%

Lantheus currently has a consensus target price of $108.11, suggesting a potential upside of 7.52%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 53.77%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Lantheus beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Liquidia?

Compass Pathways (NASDAQ:CMPS) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, Liquidia had 4 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Liquidia and 7 mentions for Compass Pathways. Liquidia's average media sentiment score of 0.74 beat Compass Pathways' score of 0.04 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways presently has a consensus target price of $23.36, suggesting a potential upside of 53.77%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 46.66%. Given Compass Pathways' stronger consensus rating and higher probable upside, equities analysts plainly believe Compass Pathways is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Liquidia has a net margin of 30.74% compared to Compass Pathways' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Liquidia	30.74%	149.65%	36.30%

Compass Pathways has a beta of 2.54, indicating that its stock price is 154% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Liquidia has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Liquidia	$158.32M	37.81	-$68.92M	$1.37	48.82

Summary

Liquidia beats Compass Pathways on 11 of the 15 factors compared between the two stocks.

How does Compass Pathways compare to Amneal Pharmaceuticals?

Compass Pathways (NASDAQ:CMPS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 7 mentions for Compass Pathways. Amneal Pharmaceuticals' average media sentiment score of 0.49 beat Compass Pathways' score of 0.04 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways currently has a consensus price target of $23.36, indicating a potential upside of 53.77%. Amneal Pharmaceuticals has a consensus price target of $20.14, indicating a potential upside of 7.66%. Given Compass Pathways' higher probable upside, research analysts clearly believe Compass Pathways is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Amneal Pharmaceuticals has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Compass Pathways' net margin of 0.00%. Compass Pathways' return on equity of -49.63% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Compass Pathways has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Compass Pathways on 10 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Compass Pathways (NASDAQ:CMPS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Compass Pathways	N/A	-49.63%	-13.08%

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

Definium Therapeutics presently has a consensus price target of $64.88, suggesting a potential upside of 67.16%. Compass Pathways has a consensus price target of $23.36, suggesting a potential upside of 53.77%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Definium Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Definium Therapeutics had 37 more articles in the media than Compass Pathways. MarketBeat recorded 44 mentions for Definium Therapeutics and 7 mentions for Compass Pathways. Definium Therapeutics' average media sentiment score of 0.34 beat Compass Pathways' score of 0.04 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	8 Very Positive mention(s)	11 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Definium Therapeutics beats Compass Pathways on 8 of the 14 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.08B	$12.45B	$7.24B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-3.29	797.25	275.79	25.40
Price / Sales	N/A	950.97	695.58	114.44
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	-27.62	10.53	10.46	6.33
Net Income	-$287.86M	$2.82B	$3.49B	$358.33M
7 Day Performance	5.85%	1.69%	0.59%	1.12%
1 Month Performance	8.42%	0.83%	-2.01%	-2.67%
1 Year Performance	210.00%	3.90%	18.09%	6.01%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	2.4361 of 5 stars	$15.19 +1.3%	$23.36 +53.8%	+199.0%	$2.08B	N/A	N/A	156
BLTE Belite Bio	3.662 of 5 stars	$173.00 -0.5%	$218.73 +26.4%	+133.4%	$7.00B	N/A	N/A	41	Gap Down
LNTH Lantheus	3.8013 of 5 stars	$100.32 +0.1%	$108.11 +7.8%	+95.0%	$6.54B	$1.54B	24.23	1,193
LQDA Liquidia	3.9263 of 5 stars	$65.31 -2.1%	$98.08 +50.2%	+171.1%	$5.97B	$158.32M	47.67	216	Insider Trade
AMRX Amneal Pharmaceuticals	3.3662 of 5 stars	$17.22 +1.2%	$19.57 +13.7%	+90.7%	$5.43B	$3.02B	35.14	8,500	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Compass Pathways compare to Belite Bio?

Summary

How does Compass Pathways compare to Lantheus?

Summary

How does Compass Pathways compare to Liquidia?

Summary

How does Compass Pathways compare to Amneal Pharmaceuticals?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Compass Pathways compare to Belite Bio?

Which has more risk & volatility, CMPS or BLTE?

Does the media favor CMPS or BLTE?

Is CMPS or BLTE more profitable?

Do insiders and institutionals have more ownership in CMPS or BLTE?

Do analysts recommend CMPS or BLTE?

Which has preferable earnings and valuation, CMPS or BLTE?

Summary

How does Compass Pathways compare to Lantheus?

Do insiders & institutionals hold more shares of LNTH or CMPS?

Does the media favor LNTH or CMPS?

Which has stronger valuation and earnings, LNTH or CMPS?

Which has more risk & volatility, LNTH or CMPS?

Is LNTH or CMPS more profitable?

Do analysts prefer LNTH or CMPS?

Summary

How does Compass Pathways compare to Liquidia?

Does the media favor CMPS or LQDA?

Do analysts rate CMPS or LQDA?

Is CMPS or LQDA more profitable?

Which has more risk and volatility, CMPS or LQDA?

Do insiders and institutionals hold more shares of CMPS or LQDA?

Which has better earnings & valuation, CMPS or LQDA?

Summary

How does Compass Pathways compare to Amneal Pharmaceuticals?

Does the media refer more to CMPS or AMRX?

Do analysts recommend CMPS or AMRX?

Which has preferable earnings and valuation, CMPS or AMRX?

Do insiders & institutionals have more ownership in CMPS or AMRX?

Is CMPS or AMRX more profitable?

Which has more risk and volatility, CMPS or AMRX?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Is DFTX or CMPS more profitable?

Which has higher valuation and earnings, DFTX or CMPS?

Which has more risk and volatility, DFTX or CMPS?

Do analysts rate DFTX or CMPS?

Do institutionals & insiders have more ownership in DFTX or CMPS?

Does the media prefer DFTX or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools